Idexx Laboratories Inc
Q2 2025 Earnings
Market Reaction
Did IDXX Beat Earnings? Q2 2025 Results
IDEXX Laboratories posted a clear-cut beat in the second quarter of 2025, with earnings per share of $3.63 clearing the $3.30 consensus estimate by nearly 10% and revenue of $1.11 billion topping expectations by 3.95% while growing 10.6% year over year. The single most compelling driver of the quarter was the commercial launch of the IDEXX inVue Dx analyzer, which generated nearly 2,400 placements and sent CAG Diagnostics capital instrument revenues up 66% reported, pulling broader Companion Animal Group results along with 10% organic growth. VetLab consumables expanded 15% reported on the back of stronger testing utilization and a growing premium instrument installed base, reinforcing the recurring revenue durability that underpins the IDEXX model. Gross margin expanded 90 basis points to 62.6%, and operating margin reached 33.6%. Management responded to the momentum by raising full-year revenue guidance to a range of $4.21 billion to $4.28 billion and lifting EPS guidance to $12.40 to $12.76, projecting 7% to 9% organic revenue growth; analyst price target increases following the report reflect growing confidence in that trajectory.
- Record quarterly instrument placements driven by IDEXX inVue Dx adoption
- IDEXX VetLab consumables revenue growth of 15% reported with testing utilization gains
- 10% growth in global premium instrument installed base
- Strong net customer gains and solid price realization
- CAG Diagnostics recurring revenue growth of 9% reported and 7% organic
- International CAG Diagnostics recurring revenue growth of 15% reported and 11% organic
- Gross margin expansion of 90 basis points to 62.6% from productivity initiatives and net price realization
“Our innovation-driven strategy delivered robust global growth in the second quarter. We saw exceptional momentum with IDEXX InVue Dxâ„¢ placements, exceeding expectations as veterinarians adopted this slide-free technology to streamline workflows and gain faster, more accurate clinical insights. This growth builds on the successful launch of IDEXX Cancer Dxâ„¢ in North America. Our focus on helping veterinarians gain deeper diagnostic insights to inform patient care continues to drive customer loyalty and sets a solid foundation for sustained long-term growth.”
IDEXX Laboratories CEO, on the earnings call
Forward Guidance & Outlook
IDEXX raised full-year 2025 revenue guidance to $4,205M–$4,280M (up $90M at midpoint, or ~2%), reflecting solid CAG Diagnostics recurring revenue performance, higher IDEXX inVue Dx instrument placements and revenues, and ~$70M benefit from favorable FX. Organic revenue growth outlook raised to 7%–9% (up 50 bps at midpoint). Full-year EPS guidance increased to $12.40–$12.76 (up $0.40 at midpoint), reflecting operational performance, lower effective tax rate (~21.0%), and FX benefits. Updated reported operating margin outlook of 31.3%–31.6% with comparable margin expansion of 50–80 bps. Capital expenditures projected at ~$160M. Free cash flow conversion expected at 80%–85% of net income. Reported EPS growth of 16%–20% and comparable EPS growth of 9%–13%. The company plans commercial expansions in select international regions in H2 and a modest U.S. commercial expansion.
IDXX YoY Financials
IDXX Revenue by Segment
IDXX Revenue by Geography
Figures from SEC filings and company reports. Not investment advice.